Skip to search boxSkip to navigationSkip to main content

RAGE and its ligands in bone metabolism

  • Zheng Zhou(corresponding author)
    ,
  • Wen Cheng Xiong
*Corresponding author for this work
Scholary Output:
Contribution to journal
Article
Peer-review

Open access

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well

Abstract

The receptor for advanced glycation end products (RAGE), a member of the immunoglobulin super-family transmembrane proteins, has multiple ligands, thus, is implicated in the pathogenesis of various diseases, including diabetic complications, neurodegenerative disorders, and inflammatory responses. Its function in normal physiology is beginning to be defined, and recent studies have pointed to an important role for RAGE and its ligands [e.g., HMGB1 (high mobility group box 1)] in innate immune response. In addition, RAGE and its ligands are also implicated in osteoclast activation and bone remodeling. Understanding how RAGE and its ligands regulate bone remodeling may provide insight into the pathogenesis of diabetes and chronic inflammation associated bone loss. Recent progress relevant to the functions of RAGE and its ligands in bone remodeling is discussed in this review.

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 768-776 (9 pages)

Journal (Volume, Issue Number)

Frontiers in Bioscience - Scholar (Volume 3 S, Issue 2)

Publication milestones

  • Published - 01/01/2011

Publication status

Published - 01/01/2011

ISSN

1945-0516

Publication IDs

  • Scopus: 79955956798
  • PubMed: 21196410

Publication metrics

Metrics

SciVal
citations
25
SciVal
FWCI
0.32
SciVal
Author count
2
SciVal
Paper percentile
81
Fractional count
1
Fractional count
0.50
Fractional count
1
Fractional count
0.50
Fractional count
1
Fractional count
1
Scopus
citations

PlumX, opens in new tab

Citation count
46
Captures
42

Funding Details

FundersFunding numbers
National Institutes of Health
AR048120
NIAMS
R01AR048120